The dengue virus (DENV) nonstructural protein 1 (NS1) is an immunogenic protein that holds potential for the development of vaccines and diagnostic reagents; however, the epitopes of NS1 have not been comprehensively mapped. We mapped B-cell linear epitopes on NS1 using 149 monoclonal antibodies with DENV serotype specificity and cross-reactivity as well as antisera from 27 mice immunized with the four DENV serotypes. Epitope recognition analysis was performed using a set of 15-mer sequential overlapping peptides that spanned the entire NS1 protein from DENV-1. This strategy identified three regions of NS1 that are DENV-1 serotype-specific epitopes, namely amino acid residues 1-15, 71-85, and 338-352. We also identified five group-specific B-cell epitopes that were highly conserved among isolates of the four DENV serotypes. These novel immunodominant serotype-and group-specific B-cell epitopes of DENV NS1 may aid the development of new dengue vaccines and diagnostic assays.
Introduction
Dengue, caused by dengue virus (DENV), is a major public health problem in over 100 tropical and subtropical countries (Mackenzie et al., 2004) . DENV belongs to the Flaviviridae family, which also includes yellow fever virus (YFV), West Nile virus (WNV), Japanese encephalitis virus (JEV), and tick-borne encephalitis virus (TBEV). DENV is classified into four serotypes, DENV-1, -2, -3, and -4. An infection with any of these serotypes can cause clinical manifestations including dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) (George and Lum, 1997) . Subsequent heterologous infections may increase the risk of the developing DHF or DSS (Kurane and Ennis, 1992) . Since protection against heterologous serotype infections is both partial and transient, people who live in epidemic areas may be susceptible to four DENV infections in their lifetime (Kanakaratne et al., 2009) . Thus, the cocirculation of virus serotypes in a community is the most common risk factor associated with the emergence of DHF or DSS, the most severe forms of dengue (Gubler, 1998) . Since no vaccine is available that elicits long-term protective immunity against all four DENV serotypes (Edelman, 2007; Whitehead et al., 2007) , the development of a DENV vaccine remains a global public health challenge. A better understanding of how viral components correlate with immune protection and pathogenic determinants is likely to contribute to the development of an effective vaccine. In addition, given the lack of an effective vaccine for controlling dengue, early identification of multiple DENV infections in the acute phase of the illness is important for reducing morbidity and mortality associated with DHF and DSS, as well as for epidemiological control in areas where multiple flaviviruses are endemic (De Paula and Fonseca, 2004) .
The DENV nonstructural protein 1 (NS1) has been identified as a candidate antigen for vaccine development (Costa et al., 2006 (Costa et al., , 2007 . Immunization with NS1 or passive administration of anti-NS1 MAbs can protect mice against a lethal virus challenge (Chung et al., 2006; Falgout et al., 1990; Henchal et al., 1988; Schlesinger et al., 1987) . However, NS1 is also associated with dengue pathogenesis, which may elicit autoantibodies that react with platelet and extracellular matrix proteins to induce platelet dysfunction and bleeding (Chang et al., , 2009 Falconar, 1997; Sun et al., 2007) , directly enhance infection (Alcon-LePoder et al., 2005) , and promote the formation of terminal complement complex by binding the human complement regulatory protein clusterin (Kurosu et al., 2007) . Dengue pathogenesis can also result in endothelial cell apoptosis and immune activation via anti-NS1 antibody-dependent complement-mediated cytolysis (Lin et al., 2005 (Lin et al., , 2003 (Lin et al., , 2008 or by binding of soluble NS1 and subsequent recognition by anti-NS1 antibodies (Avirutnan et al., 2007) . NS1 has also been identified as being both a group-specific and serotype-specific determinant and as an early serotyping diagnostic marker (Falconar and Young, 1991; Henchal et al., 1987; Shu et al., 2000; . Serotyping assays have been developed using serotype-or group-specific monoclonal antibodies (MAbs) to differentiate the four serotypes of DENV infections (Qiu et al., 2009; Xu et al., 2006; Young et al., 2000) . Identification and characterization of antigenic NS1 epitopes may help us elucidate the dengue pathogenesis, accelerate vaccine design, and further develop immunodiagnostic reagents. In our previous study, we generated and characterized MAbs that recognize serotype-specific epitopes and group-specific epitopes on DENV NS1 (Qiu et al., 2009; Xu et al., 2006) . In the present study, we identified several immunodominant epitopes on NS1 using a panel of MAbs and antisera raised in mice against the four DENV serotypes. Characterization of the immunodominant sites provides information that has great potential value for developing dengue diagnostic reagents and for designing better dengue vaccines.
Results

Serotype specificity and cross-reactivity of MAbs raised against NS1
A total of 149 hybridoma cell lines that stably produced MAbs were established on the basis of their strong reactivity with both recombinant NS1 protein and DENV-infected cell lysates as antigen in the ELISA. Immunofluorescence assays (IFA) showed that all MAbs recognized the native NS1 antigen in DENV-infected cells. Most of the MAbs were IgG1 subtype antibodies. The serotype specificity and cross-reactivity of the MAbs were further characterized by testing their reactivity with each virus serotype by ELISA and Western blot analysis. Of 149 MAbs, 25 MAbs, 20 MAbs (Qiu et al., 2009) , 15 MAbs, and 15 MAbs reacted exclusively with the DENV-1 NS1, DENV-2 NS1, DENV-3 NS1, and DENV-4 NS1 proteins, respectively, in ELISA plus Western blotting or IFA assays. The remaining 74 MAbs showed various patterns of cross-reactivity with the four DENV serotypes. The characteristics of representative MAbs are summarized in Table 1 and Fig. 1 .
Identification of serotype-and group-specific B-cell epitopes on NS1 protein using MAbs A total of 149 MAbs described above were tested for binding to a set of overlapping 15-residue synthetic peptides that spanned the entire amino acid sequence of NS1 from DENV-1 by ELISA (Table 2) . The data for MAbs specifically reactive with the overlapping peptides are summarized in Table 1 . As expected, all of the serotype-specific MAbs to each virus serotype reacted exclusively with NS1 from the corresponding serotypes; for example, MAbs specific for DENV-2, DENV-3, or DENV-4 failed to react with any of the synthetic peptides derived from DENV-1 NS1. Among the 25 DENV-1 serotype-specific MAbs, six MAbs (5A48A3, 5A65A2, 5B29A1, 5B71A8, 5C29A3, and 5E68A17) showed a strong reaction with peptide 1 (residues 1-15); one MAb (5D25A2) reacted specifically with peptide 8 (residues 71-85); four MAbs (5A30A3, 5A70A5, 5A75A9, and 5A78A3) reacted Table 1 Characteristics of representative MAbs against the NS1 protein from each DENV serotype.
Origin of MAbs
Clones
Isotypes ELISA results from recombinant NS1 Western blot results from recombinant NS1
IFA results from cells infected by: Binding Peptide DENV-1 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 DENV-1 DENV-2 DENV-3 DENV-4 Fig. 2 . The specific reactivity of peptides with MAbs was further conformed by competitive inhibition experiments (Supplemental data). The MAbs, which reactivity with peptide 1 (residues 1-15) and peptide 12 (residues 111-125), respectively, binding to solid phase DENV-1 NS1 protein were efficiently inhibited (N75% inhibition) by the corresponding soluble peptide. The MAbs, which reactivity with peptide 8 and 35, respectively, binding to solid phase DENV-1 NS1 protein were partially inhibited (32-73% inhibition) by the corresponding soluble peptides, but the binding of MAbs were completely inhibited (61-91% inhibition) when increasing soluble peptides at a concentrations of 100 μg/mL. The remaining 11 MAbs, three MAbs also showed weaker reaction with a numbers of the other peptides (data not shown), but the binding of MAbs to DENV-1 NS1 protein was not inhibited (b25% inhibition) by the corresponding soluble peptide even increasing concentrations of soluble peptides, which were probably due to nonspecific reactions. Another 8 MAbs, which did not react with DENV-1 NS1 on Western blots, failed to bind any of the overlapping peptides, suggesting that these MAbs were directed against conformational or discontinuous epitopes. We compared NS1 sequences in different members of the flavivirus family by aligning NS1 residues 1-15, 71-85, 111-125, and 338-352 from DENV-1, -2, -3, -4, WNV, YFV, and JEV. Alignment revealed that the amino acid sequences of peptide 1 (residues 1-15), peptide 8 (residues 71-125), and peptide 35 (residues 338-352) were completely conserved among DENV-1 serotypes, but different among the flaviviruses, suggesting that three regions of NS1, i.e. peptide 1 (residues 1-15), peptide 8 (residues 71-125), and peptide 35 (residues 338-352), were DENV-1 serotype specific epitopes. Further studies were carried out to characterize the crossreactivity of 74 MAbs to the synthetic NS1 peptides; these MAbs had shown different cross-reactivity patterns to four DENV serotypes. As shown in Table 1 , a set of 4 MAbs (three MAbs derived from DENV-1 immunized mice and one MAb derived from DENV-2 immunized mice) reacted specifically with peptide 3 (residues 21-35); 9 MAbs (one MAb derived from DENV-1 immunized mice, four MAbs derived from DENV-2 immunized mice, and four MAbs derived from DENV-3 immunized mice) reacted specifically with peptide 12 (residues 111-125); 14 MAbs (six MAbs derived from DENV-1 immunized mice, one MAb derived from DENV-2 immunized mice, and seven MAbs derived from DENV-4 immunized mice) reacted specifically with peptide 20 (residues 191-205); 2 MAbs (one MAb derived from DENV-1 immunized mice and one MAb derived from DENV-4 immunized mice) reacted specifically with peptide 27 (residues 261-275); and 3 MAbs derived from DENV-2 immunized mice reacted specifically with peptide 30 (residues 291-305). The results of cross-reactive MAbs specifically reactive with the overlapping peptides are summarized in Fig. 3 . The specific reactivity of peptides with MAbs was further conformed by competitive inhibition experiments (Supplemental data). The binding of MAbs to solid phase DENV-1 NS1 protein was efficiently inhibited (N75% inhibition) by the corresponding soluble peptide. The remaining 42 MAbs, some showed weaker reaction with a numbers of the other peptides (data not shown) but the binding of MAbs to solid phase DENV-1 NS1 protein was not inhibited (b25% inhibition) by the corresponding soluble peptide, which were probably due to nonspecific reactions; some did not react with any of the peptides, which were probably directed against conformational or discontinuous epitopes or that the epitopes they bound to on NS1 did not exist. NS1 sequences from different members of the flavivirus family were compared by aligning NS1 residues 21-35, 111-125, suggesting that five regions of NS1, i.e. peptide 3 (residues 21-35), peptide 12 (residues 111-125), peptide 20 (residues 191-205), peptide 27 (residues 261-275), and peptide 30 (residues 291-305), were group-specific epitopes. Identification of immunodominant serotype-and group-specific B-cell epitopes on NS1 using mouse antisera Antisera from 27 mice, each injected with one of the four DENV serotypes (9 mice with DENV-1 NS1, 4 mice with DENV-2 NS1, 4 mice with DENV-3 NS1, and 10 mice with DENV-4 NS1), were analyzed for binding to a set of overlapping synthetic peptides. The results of binding to the immunodominant serotype-and group-specific epitopes are summarized in Fig. 4 . Peptide 1 (residues 1-15) showed high immunoreactivity, i.e. a high mean absorbance/cut-off ratio, with sera from DENV-1 NS1-immunized mice. This suggests that the region of NS1 comprising residues 1-15 is a serotype-specific immunodominant epitope. Peptide 3 (residues 21-35) reacted with sera from DENV-1-and DENV-2-immunized mice; the high mean absorbance/cut-off ratio was different from that of sera from DENV-3-and DENV-4-immunized mice, suggesting that this region is a DENV-1 and DENV-2 serotype-specific immunodominant epitope. Peptides 12 (residues 111-125), 20 (residues 191-205) , and 27 (residues 261-275) had high cross-immunoreactivity with sera from mice immunized with each of the four DENV serotypes. This suggests that the three regions are group-specific immunodominant epitopes among the four DENV serotypes. Taken together, these data suggest that the most immunoreactive epitopes on the NS1 protein involve amino acid residues 1-15, 21-35, 111-125, 191-205, and 261-275 .
Identification of conserved serotype-and group-specific B-cell epitopes on NS1 by sequence alignment
There are 675 DENV-1, 622 DENV-2, 396 DENV-3, and 64 DENV-4 isolate sequences available in the NCBI Entrez protein database (http:// www.ncbi.nlm.nih.gov/protein/) that can be used for sequence alignment analysis. Alignment of the serotype-specific epitopes (residues 1-15, 71-85, and 338-352) of NS1 from DENV-1 isolates revealed a high degree of conservation of 100% homology for the 3 epitopes in 668, 633, and 532 of the 675 DENV1 isolates, respectively, with amino acid identity ranging from 78.8-99%. Alignment of group-specific epitopes (residues 21-35, 111-125, 191-205, 261-275 (Table 3 ), indicated that these regions of NS1 are highly conserved among the four DENV serotypes. (Falconar et al., 1994; Green et al., 1997; Mathew et al., 1998) . The identification of epitopes on NS1 is important for designing subunit vaccines and for developing serological tests that can differentiate infections caused by the four DENV serotypes. B-cell epitopes are more commonly characterized based on their amino acid sequences than are T-cell epitopes (Carter and Loomis-Price, 2004) . In this study, we produced MAbs and sera by immunizing mice with the NS1 protein from each DENV serotype. These MAbs and sera were used for detailed characterization of the immunodominant serotype-and group-specific B-cell epitopes on NS1 based on their binding to synthetic peptides from the NS1 sequence of the DENV-1 serotype.
Discussion
DENV NS1 effectively induces specific B-and T-cell responses to elicit protection against virus infection
Using a panel of well-characterized DENV-1 serotype-specific MAbs, we identified three novel serotype-specific B-cell epitopes, Fig. 4 . Immunodominant epitope mapping of NS1 protein using mouse antisera. Reactivity of mouse antisera with synthesized overlapping peptides spanning the entire sequences of the NS1 protein derived from DNEV-1 was determined as described in Materials and methods. The y-axis shows the mean reactivity (absorbance/cutoff) of sera from immunized mice with synthetic peptides plus standard error bars. The data represent the average of two independent experiments. The significance of the differences in ELISA reactivity of peptides with sera from each DENV immunized mice was analyzed using the SPSS statistical package, version 13.0, for one-way ANOVA analysis, (⁎): The reactivity of sera from DENV-1 NS1 immunized mice with peptide 1 was significantly higher than the reactivity of sera from mice immunized with the other three DENV serotypes (P b 0.05). ( ): The reactivity of sera from DENV-1 NS1 immunized mice with peptide 3 was similar to that of sera from DENV-2 NS1 immunized mice significantly higher than that of sera from DENV-3 and DENV-4 immunized mice (P b 0.05). (#): The reactivity of sera from mice immunized with DENV-1, -2, -3, or -4 NS1 with peptides 8, 12, 20, 27, and 35 was not significantly different (P N 0.05), and the reactivity of peptides 12, 20, and 27 with high mean of absorbance/cut off value ratio between the four DENV immunized mice sera. ( §): The reactivity of sera from DENV-3 NS1immunized mice with peptide 30 was significantly higher than the reactivity of sera from DENV-1 NS1 immunized mice but was similar to that of sera from DENV-2 and DENV-4 NS1 immunized mice (P b 0.05). comprising NS1 amino acid residues 1-15, 71-85, and 338-352. Alignment of amino acid sequences from a number of DENV-1 isolates indicated that the three serotype-specific B-cell epitopes are highly conserved among DENV-1 strains. In addition, we identified five group-specific B-cell epitopes that were associated with NS1 amino acid residues 21-35, 111-125, 191-205, 261-275, and isolates from the four DENV serotypes. Furthermore, using a combination of specific MAbs and sera from immunizing mice with each DENV serotype, we showed that several B-cell epitopes on the NS1 protein identified in this study demonstrated that there are at least five immunodominant epitopes on NS1 (residues 1-15, 21-35, 111-125, 191-205, and 261-275) . Our results indicated that the NS1 protein contains multiple immunodominant Bcell epitopes that are capable of eliciting strong antibody responses. By studying the five immunodominant epitopes, we found that peptide 1, corresponding to NS1 amino acid residues 1-15, showed significantly higher reactivity with sera from DENV-1-immunized mice sera and with six of 25 serotype-specific MAbs (24%; Figs. 2 and 4). This suggests that this region is an immunodominant serotypespecific epitope on DENV-1 NS1. This immunodominant epitope is consistent with reports by Huang (Huang et al., 1999) , who identified a peptide, residues 1-15 derived from DENV-2 NS1, as an immunodominant epitope that reacted with most sera from four DENV infection patients. Our independent identification of residues 1-15 from DENV-1 NS1 as the exclusive epitope responsible for the reactivity of serotype-specific MAbs and antisera from DENV-1 immunized mice is strong evidence that this is a serotype-specific epitope. However, further study is needed to determine the specific binding activity of this region using sera from dengue patients. In addition, an immunodominant epitope that mapped to residues 111-125 in the present study appeared to define a group-specific B-cell epitope similar to that identified by Falconar (Falconar et al. 1994 ). We subsequently determined that this region, comprising the amino acid sequence 112 KYSWKSWGKAK 123 , is highly conserved among the four DENV isolates (Table 3) ; there is a substitution of residues117 S by T in DENV-2, -3, -4 isolates, but this amino acid substitution is antigenically silent, as demonstrated by Falconar (Falconar et al., 1994) . Other study reported that the NS1 amino acid residues 111 HKYSWK 116 from DENV-1 was defined as a DENV-1 serotypespecific B-cell epitope on NS1 by a DENV-1 serotype specific MAb (Wu et al., 2001) . They suggested that His111 was the most important amino acid residue for antibody binding specificity, since a substitution of residues111 H by L in DENV-2, -3, and -4 isolates, markedly decreased the specificity of MAb reactivity. Interestingly, in this study we found that residues 111 HKYSWKSWGKAKIIG 125 of NS1 reacted more strongly with cross-reactive MAbs than with serotype-specific MAbs (3 DENV-1 serotype-specific MAbs reacted weakly). Considering both data from previous reports and our own findings, we suggest that the NS1 epitope residues 111-125 is most likely an immunodominant group-specific epitope. The other group-specific epitopes described here, comprising amino acid residues 21-35 on NS1, is distinct from the epitope reported by Falconar (Falconar et al., 1994) . In their report, the 25 VHTWTEQYK 33 region only reacted with DENV-2 serotype-specific MAbs; when this region had additional flanking residues on the N or C-terminus, the serotype-specific MAbs showed weaker binding activity, suggesting that additional flanking residues on 25 VHTWTEQYKFQ 35 on the N or C-terminus is probably for crossreactive MAb binding. Further investigation will determine whether amino acid substitution in peptide 3 (residues 21-35) affects antibody binding and which amino acid(s) on the peptide are crucial for antibody binding.
Understanding the MAb-specific epitope-binding sites on DENV NS1 and characterizing its immunodominant sites may provide valuable information for the development of dengue diagnostic tests and vaccines. Since amino acid sequences for the four DENV serotypes show homology ranges from 63.2% to 78.7% (Westaway and Blok, 1997) , share antigenic epitopes inducing cross-reactive antibodies among flaviviruses has been a diagnostic challenge. Currently, serological assays cannot distinguish the four DENV serotypes and other flaviviruses. The MAb-specific epitopes reported here might aid development of diagnostic tests that can discriminate between different DENV serotypes. In a previous study, we successfully developed two serotype-specific NS1 antigen assays using serotype-specific MAbs to distinguish the DENV serotypes (Qiu et al., 2009; Xu et al., 2006) . Thus, the unique serotype-specific B-cell epitopes located on NS1 that are reported in the present study may be useful for accurate serodiagnosis of DENV infection.
Identification of novel antigenic cross-reactive epitopes for the four DENV serotypes should provided insights into the humoral immunity of dengue disease. The pathogenesis of DHF or DSS is not well understood. Several studies have reported that antibody responses to NS1 play a role in the development of DHF or DSS (Chen et al., 2009; Lin et al., 2005; Sun et al., 2007) . Determination of the epitopes on NS1 that are responsible for the harmful vs. beneficial effects of this protein might provide greater understanding of the pathogenesis of dengue disease and speed NS1-based vaccine development. Further studies are needed to determine the epitope profiles in clinical serum samples and to analyze the functional roles of epitope-specific MAbs in dengue pathogenesis and immunoprotection.
Materials and methods
Viruses
The four DENV serotype strains (DENV-1, Hawaii; DENV-2, New Guinea-C; DENV-3, Guanxi-80-2; and DENV-4, H241) used in this study were obtained from the Center for Disease Control and Prevention in Guangzhou, P. R. China. The viruses were propagated in C6/36 cells in Eagle's minimal essential medium at 33°C for 3 to 5 days. After cytopathic effects were observed, the viral culture supernatants and infected cell lysates were collected and kept frozen at −80°C until use.
Recombinant NS1 protein
Recombinant NS1 proteins from the four DENV serotypes were prepared as described previously (Qiu et al., 2009; Xu et al., 2006) . Briefly, the gene encoding the NS1 protein from each DENV serotype was cloned into pQE30 (Qiagen, Hilden, Germany) in-frame and downstream of the 6xHis tag coding sequence. The 6xHis-tagged recombinant NS1 protein from each DENV serotype was expressed in an Escherichia coli host strain (M15) and purified by Ni-nitrilotriacetic acid affinity chromatography (Qiagen) according to the manufacturer's instructions.
Peptide synthesis
A set of 35 overlapping, biotinylated 15-mer peptides that encompassed the entire NS1 protein amino acid sequence from the DENV-1 serotype (Hawaii strain X69395.1) were synthesized commercially by Huachen Biological Technology Co. Ltd (Xi'an, P. R. China). Peptides were 15 amino acid residues in length, with adjacent peptides overlapping by five residues (Table 2 ). Synthesized peptides were purified (final purityN 90% as determined by high-performance liquid chromatography. The purity of each peptide was confirmed by laser desorption mass spectrometry. Freeze-dried peptides were dissolved in 100% dimethyl sulfoxide to an approximate concentration of 1 mg/mL and stored at −80°C until use.
Production of mouse antisera BALB/c male mice (4-6 weeks old) were immunized intradermally with a combination of purified recombinant NS1 protein derived from each DENV serotype and with the corresponding DENV-infected cell culture supernatant (inactive) as an immunogen mixed with Freund's complete adjuvant (Sigma-Aldrich). The immunogen was boosted with Freund's incomplete adjuvant at 10-day intervals. Mouse antisera were collected after five immunizations.
Production and characterization of MAbs
The production and identification of MAbs against the NS1 protein from the four DENV serotypes was performed as described previously (Qiu et al., 2009; Xu et al., 2006) . Briefly, BALB/c mice were immunized as described above. The spleenocytes from the immunized mice were harvested and fused with NS-1 myeloma cells. The hybridoma cell lines were screened by indirect ELISA using recombinant NS1 protein and DENV-infected cell lysate as coating antigens respectively. The screening was confirmed by an IFA that detected MAb binding on C6/36 cells infected with each DENV serotype, as described previously (Che et al., 2005; Qiu et al., 2009; Xu et al., 2006) . Positive hybridoma cells were cloned by limiting dilution. The serotype specificity and cross-reactivity of the MAbs were evaluated by ELISA and Western blot analysis using recombinant NS1 proteins from the four DENV serotypes as well as by using cell lysates from cells infected with each DENV serotype. The isotypes of the MAbs were determined using a commercially available mouse MAb isotyping kit (Zymed Laboratories, Carlsbad, CA). The MAbs were purified by using protein G column chromatography (AmershamPharmacia) according to the manufacturer's instructions.
Epitope mapping using ELISA
The reactivity of mouse antisera and MAbs with the overlapping, biotinylated peptides were determined by ELISA. Briefly, 96-well microplates (Costar Corning Inc., Corning, NY) were coated with 100 μL/well streptavidin (5 μg/mL; Sigma-Aldrich) in 0.1 M carbonate buffer (pH 9.6) at 4°C overnight. Wells were blocked overnight at 4°C using a blocking reagent. After removing the blocking solution, a series of biotinylated peptides at concentration of 5 μg/mL were added and incubated for 2 h at room temperature. After the plates were washed, mouse antisera at a dilution of 1:1000 or MAb at a concentration of 5 μg/mL was added and incubated for 30 min at room temperature. After the plates were washed, 1:1,000 dilution HRP-conjugated goatantimouse IgG (Zymed Laboratories, was added and incubated for 30 min at room temperature. After washing, tetramethylbenzidine (KPL, Gaithersburg, MD) solution was added; after incubation for 10 min, and the reaction was stopped with 0.3 M sulfuric acid. The absorbance was measured at 450 nm in a microplate autoreader (BioTek Instruments, USA). Each sample was tested in duplicate wells. An irrelevant MAb and normal mouse serum were used as controls. The reactivity of the MAb with the synthesized peptides was considered positive when the mean absorbance value was ten-fold greater than the mean absorbance value of the MAb control. The reactivity of mouse antiserum with the synthesized peptides was calculated using the ratio of the mean absorbance/cut-off value. The cut-off value was determined for each peptide by incubation with sera from five normal mice. The mean absorbance using the five normal mice sera was considered the cutoff value for a peptide.
Competitive ELISA
Microplates (Costar Corning Inc) were coated with 100 μL/well of DENV-1 NS1 protein at concentration of 1 μg/mL in coating buffer. The dilutions of MAbs giving an optical density of approximately 2.0 were selected for subsequent competitive experiments. The MAb at selected dilutions in 60 μL of PBS containing 0.1% of BSA was mixed with the 60 μL of PBS containing 0.1% of BSA containing increasing concentrations of soluble synthetic peptides (ranging between 1.56-100 μg/mL). After 1 h of incubation at 37°C, 100 μL of mixtures were transferred into the microplates precoated DENV-1 NS1 protein and the plates incubated for 1 h at 37°C. After the plates were washed, 100 μL/well of a 1:1000 dilution HRP-conjugated goat antimouse IgG (Zymed Laboratories) was added and incubated for 30 min at 37°C. After further washing, 100 μL/well of tetramethylbenzidine (KPL) solution was added, and the reaction was stopped after incubation for 10 min with 0.3 M sulfuric acid. The absorbance was measured at 450 nm in a microplate autoreader (Bio-Tek Instruments, USA). The mixture of same MAb and PBS without synthetic peptides was used as a control. The percentage of inhibition was calculated by the following formula: [1 − (OD 450 of the test well/OD 450 of the control well)] × 100% (where OD 450 is the optical density at 450 nm). The results were described as follows: inhibition of N75% represented competitive binding, inhibition from 25% to 75% represented relatively competitive binding, and inhibition of b25% represented noncompetitive binding.
Statistical analysis
The SPSS statistical package, version 13.0, was used to perform one-way ANOVA analysis to compare the reactivity of the synthetic peptides with sera from mice immunized with the four DENV serotypes in the ELISA i.e. to determine whether reactivity was significantly different. P values b0.05 were considered statistically significant.
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